

LUNG CANCER SYMPOSIUM ON TARGETED THERAPY

Prof. Niels Reinmuth, Ronny Öhman, Ana Carneiro

Stockholm, June 2025

Till: Specialister med intresse för NSCLC / CC: Verksamhetschef

We are pleased to invite you to the meeting "**Lungcancer Symposium on Targeted Therapy**" in Lund on **September 30, 2025**. During this meeting, experts will discuss the latest insights in the treatment of targeted therapy in NSCLC with focus on BRAF mutated NSCLC.

Special invited speaker: Professor Niels Reinmuth, Asklepios Lung Clinic Gauting, München, Germany, Senior consultants Ronny Öhman, and Ana Carneiro at Skåne University Hospital in Lund.

Venue: **Föreläsningssal 4, Blocket, Skånes universitetssjukhus Lund**.
The meeting will be streamed live as well. **Register below**.

Program

16:00 – 16:30	Coffee	17:45 – 18:00	Break
16:30 – 16:40	Introduction, Senior Consultant Ronny Öhman, Skåne University hospital Lund	18:00 – 18:30	Patient cases and discussion, Senior Consultant Ronny Öhman, and Prof Niels Reinmuth
16:40 – 17:25	Challenges and future directions for treatment of NSCLC with oncogenic mutations, Prof. Niels Reinmuth, Asklepios Lung Clinic Gauting, München, Germany	18:30 – 18:40	Closing remarks, Senior Consultant Ronny Öhman
17:25 – 17:45	Practical experience from Malignant Melanoma, Senior Consultant Ana Carneiro, Skåne University hospital Lund	18:40	Walk to restaurant

Registration

Prof Niels Reinmuth background

Dr Niels Reinmuth is a certified physician in "General Medicine", "Haematology and General Oncology", and "Pneumology". He was awarded a post-doctoral lecturing qualification by the University of Heidelberg, Germany.

From 2012 until February 2016, Niels Reinmuth worked as Senior Physician at the Lung Clinic Grosshansdorf, Department of Thoracic Oncology, Grosshansdorf, Germany.

Since March 2016, Niels Reinmuth has been leading the Thoracic Oncology Department at the Asklepios Lung Clinic in Munich-Gauting, Germany.

Dr Reinmuth's main interests are targeted therapies in non-small-cell lung cancer, new approaches in small-cell lung cancer and modern therapies in malignant pleural mesothelioma, as well as translational research related to predictive markers.

Dr Reinmuth is member of the German Cancer Society, the German Society of Pulmonology, the International Association for the Study of Lung Cancer (IASLC), the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO).

Best regards,

Veronica Kalhori
Medical Advisor
veronica.kalhori@pierre-fabre.com

Michael Rustner
Sr Key Account Manager
michael.rustner.ext@pierre-fabre.com

The shipment is sent with the support of information from the Health and Medical Care Address Register, HSAR, by Pierre Fabre Pharma Norden AB, which is connected to the Privacy Protection Program for HSAR. Additional information about address details and registration can be obtained via www.hsar.se or by phone at 08-555 214 20.

Pierre Fabre will use your contact details to book the meeting. Pierre Fabre is responsible for the processing of personal data in this case, in a way that can ensure security and confidentiality levels, in accordance with the EU General Data Protection Regulations (GDPR) effective from May 2018. Pierre Fabre stores and uses the personal data collected from you. Your personal information (name, address, telephone number, e-mail) provided in this case is only saved as long as it is required for the administration. At any time, you can exercise your right to access and rectify your personal data by email to the following address infororden@pierre-fabre.se.